Li Lu

Li Lu

Auto-generated profile, based on publicly available information

Li Lu

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200030, P.R. China

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2025 in Cell Reports Medicine
Verified
Journal Article
Open access
ZCZhengqi Cao
Zhengqi Cao
ZMZhouwenli Meng
Zhouwenli Meng
JLJian Li
Jian Li
YTYu Tian
Yu Tian
LLLi Lu
Li Lu
ZLZiming Li
Ziming Li
Conventional neoadjuvant chemotherapy provides limited benefit for patients with resectable non-small cell lung cancer (NSCLC). Recently, neoadjuvant chemoimmunotherapy (NCIT) has transformed the perioperative management of NSCLC by priming systemic anti-tumor immunity before surgery, yet it remains ineffective for at least 50% of patients. Through single-cell sequencing analysis of our NCIT cohort, we identify that antigen-presenting cancer-associated fibroblasts (apCAFs) can impede the efficacy of NCIT. Using a custom cancer-associated fibroblast biobank, we uncover that interferon (IFN)-γ stimulates apCAF expansion via the JAK1/2-STAT1-IFI6/27 pathway. Mechanistically, apCAFs significantly contribute to PD-L2 expression in the tumor microenvironment (TME), triggering the accumulation of FOXP1+regulatory T cells (Tregs) through the PD-L2-RGMB axis. Reprogramming apCAFs by inhibiting the IFN-γ pathway or blocking the PD-L2-RGMB axis substantially mitigates apCAFs-mediated FOXP1+Tregs' expansion. In summary, we reveal the role of apCAFs in compromising NCIT efficacy and propose applications for anti-PD-L2/RGMB regimens to synergize with anti-PD1 therapies by targeting apCAFs.

31 January 2014 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
JCJun Chen
Jun Chen
HZHengjie Zhang
Hengjie Zhang
XZXuling Zhang
Xuling Zhang
GYGuozhu Yang
Guozhu Yang
LLLi Lu
Li Lu
QLQingnan Li
Qingnan Li

17 December 1995 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HBHal E. Broxmeyer
Hal E. Broxmeyer
SCScott Cooper
Scott Cooper
MEMaryse Etienne‐Julan
Maryse Etienne‐Julan
XWXu‐Shan Wang
Xu‐Shan Wang
Selvarangan PonnazhaganSelvarangan Ponnazhagan
Selvarangan Ponnazhagan
ASArun Srivastava
Arun Srivastava

1 March 2014
Verified
Journal Article
Open access
PDF file
QZQinghua Zhou
Qinghua Zhou
LZLingling Zu
Lingling Zu
LLLu Li
Lu Li
XCXiaohe Chen
Xiaohe Chen
XCXiaofeng Chen
Xiaofeng Chen
ZSZhilin Sun
Zhilin Sun
Background and objective Cancer metastasis is not only the malignant marker and characteristics, but also the main cause of failure to cure and lose their life in the patients with lung cancer. Lung cancer metastasis has organ-specific characteristics. The most common sites of lung cancer metastasis are mediastinal lymph node, brain, bone, liver and adrenal gland. The aim of this study is to screen and establish lung cancer cell model with organ-specific metastasis potential with human high-metastatic large cell lung cancer cell line L9981 established by our laboratory previously, and to provide cell models for studying the mechanisms and signal regulation of organ-specific metastasis of lung cancer. Materials and methods The parent lung cancer cell line, L9981-Luc, was inoculated in the armpit of nude mice. The live animal imaging system, IVIS-200, was used to detect the lung cancer organ-specific metastasis every week. When the organ-specific metastasis were established, the nude mices bearing the lung cancer were sacrificed when they became moribund. Under sterile conditions, the organs (mediastinal lymph nodes, lung, spinal column and brain) with lung cancer organ-specific metastasis were removed and the metastasized nodules were dissected free of connective tissue and blood clots, and rinsed twice with medium. The metastasized nodules were finely minced using sterile scalpel blades in medium, and the cells were seeded in tissue culture dishes. Then, the cells with organ-specific metastasis potential were reinoculated into the armpit of nude mice, respectively. This processes were repeated to establish the organ-specific metastatic sublines of L9981-Luc cell line more than 10 times. Finally, the organ-specific metastasis sublines of L9981-Luc were screened and established, which the four cell lines have the characteristics only metastasized to brian, lung, bone and mediastinal lymph node. Results A group of organ-specific metastasis cell lines which only metastasized to brian, lung, bone and mediastinal lymph node were successfully established through repeating reinoculatation, live animal imaging in nude mice, and screening and identification in vitro. We named the four cell lines as L9981-BoM, L9981-LuM, L9981-BrM and L9981-LnM, respectively. The L9981-BoM cell was only metastasized to bone. The l9981-LuM cell was only metastasized to lung. The L9981-BrM only metastasized to brain. The L9981-LnM cell was only metastasized to midiastinal lymph nodes. Conclusions A human large cell lung cancer cell model with bone, lung, brain and lymph node-specific metastasis potential was successfully established. It will be helpful to further study the molecular mechanisms and signal regulation of lung cancer organ- specific metastasis. It will be to also provide reliable cell model for developing new techniques and molecular targeting drugs of inhibiting or reversing lung cancer metastasis. DOI: 10.3779/j.issn.1009-3419.2014.03.20

28 February 2025 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
LLLu Li
Lu Li
YGYa Gao
Ya Gao
CWChao Wu
Chao Wu
SHShizhe He
Shizhe He
MSMin Shi
Min Shi
HLHong juan Lang
Hong juan Lang
Introduction: Noninvasive respiratory support (NIRS) using helmet devices is an emerging treatment for acute respiratory failure in patients with coronavirus disease 2019 (COVID-19). However, the comparative efficacy of helmet NIRS versus other strategies in this context remains elusive. Methodology: A network meta-analysis was conducted to compare the efficacy of various NIRS strategies in randomized controlled trials (RCTs) involving COVID-19 patients with acute respiratory failure. Strategies assessed included high-flow nasal oxygen (HFNO), continuous positive airway pressure (CPAP), helmet bilevel positive airway pressure (BiPAP), and standard oxygen therapy (SOT). Relevant RCTs were identified via PubMed, Embase, and Cochrane Central Register of Controlled Trials. Outcomes of interest included intubation rate, mortality rate, length of intensive care unit (ICU) stay, and length of hospital stay. Results: Five RCTs published between 2021 and 2022 were included. Helmet BiPAP was associated with a significantly lower intubation risk compared with HFNO (relative risk (RR): 0.37, 95% confidence interval (CI): 0.16-0.86) and SOT (RR: 0.24, 95% CI: 0.10-0.62). Additionally, helmet BiPAP was linked to shorter ICU stay compared with SOT (RR: 0.10, 95% CI: 0.02-0.67). However, no significant differences were identified in mortality or hospital stay length between SOT, HFNO, CPAP, and helmet BiPAP groups. Conclusions: Helmet BiPAP is recommended over HFNO and SOT for moderate-to-severe COVID-19 patients with acute respiratory failure, due to its lower intubation risk and shorter ICU stay. No significant differences were noted in mortality or length of hospital stay among the NIRS strategies.